Business Context and Reporting Period
This Form 8-K is filed by Neuralstem, Inc. (not Palisade Bio, Inc.) for the reporting period of October 6, 2011, covering an event that occurred on October 4, 2011. The company is a Delaware corporation headquartered in Rockville, Maryland.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory disclosure regarding intellectual property and does not contain financial statements.
Material Changes
On October 4, 2011, the Company received patent allowance for U.S. Patent 8,030,492, entitled "Compositions to Effect Neuronal Growth." This represents a material development in the company's intellectual property portfolio.
Guidance, Outlook, and Risks
The filing does not provide specific financial guidance, outlook, or management commentary beyond the announcement of the patent allowance. No specific risks or contingencies are detailed in this document, though the filing references a press release (Exhibit 99.01) for further details.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.01 for details on the patent's commercial potential.
- Confirm the status of U.S. Patent 8,030,492 and its specific claims regarding neuronal growth compositions.
- Review subsequent filings to determine if this patent allowance impacts the company's product pipeline or regulatory strategy.